We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai, China, and Hyderabad, India
Healthcare providers can assess whether symptoms represent expected medication effects or require diagnostic evaluation such as stool studies, inflammatory markers (C-reactive protein, fecal calprotectin), or colonoscopy
Building on the findings from the SURMOUNT-OSA trial, which demonstrated tirzepatides efficacy in improving OSA in nondiabetic patients, this study investigated whether OSA modifies the mortality benefit associated with GLP-1 use among individuals with diabetes in a large, real-world population
Hostetler, E
It is what happens to people who treat semaglutide as a passive intervention rather than one half of an active strategy
Long-standing reputation among independent researchers